Incannex Healthcare Limited (IHL.ASX) is an innovator and developer of medicinal cannabinoid pharmaceutical products with global export capability.
IHL is currently undertaking 4 significant clinical programs to develop 4 uniquely formulated products in its relentless pursuit of FDA registration and market exclusivity over the following indications:
- Obstructive Sleep Apnoea (‘OSA’)
- Traumatic Brain Injury (‘TBI’)/Concussion
- Sepsis Associated Acute Respiratory Distress Syndrome (‘SAARDS’)
- Temporomandibular Joint Disorder (‘TMJD’).